Alfen N.V.

ALFEN

Equity

ISIN NL0012817175 / Valor 40893054

Euronext - Euronext Amsterdam (2026-07-31)

EUR 12.38-1.75%

Alfen N.V.
UMushroom community rating:

2.00 1 votes No rating yet

NegativeNeutralPositive

About company

Alfen N.V. is a Dutch company specializing in the development and provision of energy solutions, particularly in the realm of electric vehicle charging infrastructure, energy storage systems, and transformer stations. The company offers a diverse range of smart charging stations suitable for residential, commercial, and public use, with varying capacities and functionalities to meet different needs. Alfen's expertise extends to high and medium-voltage grid solutions, leveraging its extensive experience and in-house product development to provide comprehensive and efficient electricity distribution systems. The company plays a significant role in facilitating the energy transition by integrating its products to create smart and sustainable energy systems. Alfen's offerings are designed to address the increasing complexity of electricity generation, transportation, and consumption, positioning it as a key player in the evolving energy landscape.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

14.0%1Y

-80.4%3Y

-85.4%5Y

Performance

50.4%1Y

69.2%3Y

61.6%5Y

Volatility

311 M

Market cap (USD)

149,719

Daily traded volume (Shares)

11.94 / 11.57

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

2.00

1 votes

Performance:

2.00

Innovation:

3.00

Society:

4.00

Nature:

3.00

Anthony Leong

UK, 17 May 2026

Compelling energy transition play with genuine infrastructure moat, but execution has been poor — revenue declining, margins thin, and analyst consensus is Hold/Sell. Q1 2026 recovery is encouraging but needs sustained delivery before warranting conviction.

EQUITIES OF THE SAME SECTOR

Tarsus Pharmaceuticals Inc